14 June 2020 – India to begin production of Remdesivir to fight Covid-19

Type of Intervention: Other Announcement, Specific Action
Sectors Involved: Health
Intervention Categories: Drug-based measures; Finance policy and financial aid; Financial aid to health services
Level of Jurisdiction: National
Lead People/Agency: Drug Controller General of India (DCGI)

Overview: India to begin production of Remdesivir: India is soon going to have its domestic production of anti-viral Remdesivir drug, which would have safety, efficacy and stability for “restricted emergency use” on COVID-19 patients.
Full details here: https://www.hindustantimes.com/more-lifestyle/coronavirus-pandemic-india-to-begin-production-of-remdesivir-to-fight-covid-19/story-ZeoTYY7nBqVLHqGlZ4PzDL.html

Type of Justification: Advice of INTERNAL government advisory committee or group, Learning from other jurisdictions
Source of Evidence or Justification: International – government
Evidence/Justification: Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.